Fig. 1. Structures of leucinostatins A (I), B (II) and A-M (III)
Furthermore, the amino acid sequence of antibiotic 1907-11 has been elucidated only by in -beam El mass spectrometry.
In our structural studies on leucinostatins , stereochemistry of all their chiral constituents has been established.
In this paper we wish to present our experimental results leading to structural elucidations of I and II, as well as their constituents in details . hydrolysis for 20 hours, but the sample prepared by the hydrolysis for 1 hour gave primarily one peak corresponding to IV. On the other hand, in structural studies on fatty acid moiety of leucinostatin B (H) carried as in the case of I, the fatty acid IV and the butyrolactone V were identified in the ethereal extract from the hydrolysate of It. Thus, it was concluded that the fatty acid IV was the same in H as well as in I. After removal of the fatty acid moiety, the acid hydrolysate of I was subjected to measurement of FD mass spectra. Fig. 5 shows the FD mass spectrum (emitter current at 19 mA) of the hydrolysate.
The mass spectrum showed protonated molecular ions at m/z 90 (Ala), 104 (Aib), 130 (MePro), 132 (Leu) and 148 (HyLeu). However, the protonated molecular ion peaks of MOPA and of the basic component could not be observed at any emitter current. The composition of these ions were confirmed by high resolution FD mass spectrometry (see Table 1 ). The isolation followed by structural studies of the constituent amino acids of leucinostatin B (II) gave the conclusion that it was comprised of identical amino acids. Amino acid analyses of I and II substantiated the above conclusion. Table 2 (1 H, t, J=10 Hz) and 2.30 (2H, m), were observed. This consideration was confirmed by hydrolyzing XVII to yield IV and MePro. From the data mentioned above, the structures of the compound XVIH and the original fragment XVII were deduced to be 13 and 14, respectively. They mean that N-terminal residue of this antibiotic is constituted with the fatty acid IV. On the other hand, the fragment XIX whose structure was determined to be 13-Ala-DPD (15) by spectral and acid degradation studies, was isolated from the aqueous fraction. The sequences of the four fragments obtained by partial hydrolyses of leucinostatin A are summarized in Fig. 8 .
As the N-and C-terminal of leucinostatin A were blocked with the fatty acid (FA) IV and DPD, respectively, the amino acid MOPA should be placed between the fragments XVII and XIH. The abovementioned components constitute a peptide, C6YH109N11O12, which corresponds to the dehydration product of leucinostatin A.
Alumina treatment of diacetyl compound obtained by acetylation of I gave the O-monoacetyl derivative (XX); FD-MS m/z 1,264 (M-Na+) and 1,242 (MH+); IR 1) 11,C cm-1 1745 (ester), 1680 and 1660 (conjugated carbonyl). In the 400 MHz 1H NMR spectrum (Fig. 9) , the signals at 6 (ppm) 2.06 (3H, s, COCH3), 5.10 (1H, t, J=6 Hz, -CHOCOCH3), 6.15 (1H, d, Recently, the direct comparisons between leucinostatin A and antibiotic P168 (a gift of Prof. A.
Suzuixi) have been carried out and it was concluded that the two antibiotics were identical. To determine the total structure of this fragment, we have tried the mixed acylation method which have been used in mass spectrometry for peptides18,11). The fragment XXVIII was acetylated with an equimolar mixture of acetic anhydride and perdeuterioacetic anhydride to give the CH3CO/CD3CO-mixed acetylated compound (XXX), which was subjected to El and CI mass spectrometric analyses. 
